Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM581CS)

• Drug Name: CD19 and CD22 CAR-T Cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 1/2	[1]
leukaemia	2A60-2B33	Phase 1/2	[1]
Lymphoma	2A80-2A86	Phase 1/2	[2]

• Cross-matching ID: TTD Drug ID: DM581CS

Molecule-Related Drug Atlas

Drug(s) Targeting B-cell receptor CD22 (CD22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moxetumomab pasudotox	DMN63DZ	Hairy cell leukaemia	2A82.2	Approved	[3]
Inotuzumab ozogamicin	DMAC130	Acute lymphoblastic leukaemia	2A85	Approved	[4]
OspA lipoprotein	DMF5ZB3	Lyme disease	1C1G	Approved	[5]
Epratuzumab	DMI1ZXV	Acute lymphoblastic leukaemia	2A85	Phase 3	[6]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[7]
BL-22	DM8R71T	Acute lymphoblastic leukaemia	2A85	Phase 2	[8]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[9]
AUTO3	DMC5NSO	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[10]
CART-19/22	DMX0R1E	leukaemia	2A60-2B33	Phase 1/2	[11]
4SCAR19/22 T cells	DMI8TW3	B-cell lymphoma	2A86	Phase 1/2	[12]
Moxetumomab pasudotox	DMN63DZ	Hairy cell leukaemia	2A82.2	Approved	[3]
Inotuzumab ozogamicin	DMAC130	Acute lymphoblastic leukaemia	2A85	Approved	[4]
OspA lipoprotein	DMF5ZB3	Lyme disease	1C1G	Approved	[5]
Epratuzumab	DMI1ZXV	Acute lymphoblastic leukaemia	2A85	Phase 3	[6]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[7]
BL-22	DM8R71T	Acute lymphoblastic leukaemia	2A85	Phase 2	[8]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[9]
AUTO3	DMC5NSO	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[10]
CART-19/22	DMX0R1E	leukaemia	2A60-2B33	Phase 1/2	[11]
4SCAR19/22 T cells	DMI8TW3	B-cell lymphoma	2A86	Phase 1/2	[12]

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[15]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[16]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[17]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[18]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[19]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[20]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[21]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[22]
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[15]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[16]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[17]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[18]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[19]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[20]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[21]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell receptor CD22 (CD22)	TTM6QSK	CD22_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[2]
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[2]

References

• [1] ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
• [2] ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
• [3] Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
• [4] Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
• [5] Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
• [6] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [7] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [8] Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
• [9] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [10] ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
• [11] ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
• [12] ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
• [13] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [14] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [19] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [20] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [21] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [22] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL